MCL-1 inhibitors resensitizes AML to BCL-2 inhibition by regulating leukemia cell bioenergetics and carbohydrate metabolism, including the TCA cycle, glycolysis and pentose phosphate pathway and modulating cell adhesion proteins and leukemia-stromal interactions (19). This evidence concerns the gene BCL2 and leukemia.